Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline also occurs in other neurological conditions, such as Parkinson's disease, Lewy body dementia, vascular dementia, and frontotemporal dementia.
Mild cognitive impairment (MCI) is generally defined as cognitive decline that is greater than expected based on an individual's age and level of education, but does not interfere with daily function; it may be a transitional state between the cognitive changes of normal aging and dementia.1
The cholinesterase...
RELEASE
The FDA has approved Vybrique (IBSA), an oral film formulation of the phosphodiesterase type 5 (PDE5) inhibitor sildenafil, for treatment of erectile dysfunction (ED). Sildenafil oral tablets (Viagra, and generics) have been available since 1998. The manufacturer is promoting the new product as a "discreet, on-the-go" option that can be taken without water.
STANDARD TREATMENT — Oral PDE5 inhibitors (see Table 1) are generally used for initial treatment of ED. An FDA-approved, nonmedicated alcoholbased topical gel (Eroxon), which is available over the counter, improved erection response in about 60% of men who used it in clinical trials.1 Other treatment options include vacuum-assisted erection devices, intraurethral or intracavernosal alprostadil, and penile implants.2 Low-intensity extracorporeal shockwave therapy (not approved by the FDA) has gained popularity for …